Amarin Corp PLC (AMRN): Cash & Equivalents
$134.66M
As of 2025-12-31
$143.56M
As of 2026-06-30
-14.8%
3-year compound annual growth
-6.4%
5-year compound annual growth
+2.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $134.66M | +11.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $121.04M | -39.3% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $199.25M | -8.5% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $217.67M | -0.8% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $219.45M | +17.4% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $186.96M | -71.0% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $644.59M | +158.6% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $249.23M | +238.5% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $73.64M | -25.1% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $98.25M | -8.1% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $106.96M | -10.5% | 2018-02-27, Balance as of period end |
| 2014-12-31 | $119.54M | -37.6% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $191.51M | -26.4% | 2016-02-25, Balance as of period end |
| 2012-12-31 | $260.24M | +123.2% | 2015-03-03, Balance as of period end |
| 2011-12-31 | $116.60M | +270.8% | 2014-02-27, Balance as of period end |
| 2010-12-31 | $31.44M | -39.8% | 2013-02-28, Balance as of period end |
| 2009-12-31 | $52.26M | n/a | 2012-02-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $112.83M | +33.7% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
Compare AMRN, VNDA, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗